Background: Ipilimumab+nivolumab (IPINIVO) can induce durable responses in advanced melanoma, but many patients experience progression at some point. It is currently unknown to what extent these pati…

Read more about 'Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy had a considerable response rate, acceptable safety profile, and potential for a durable response'...

Posted in Research; Posted 5 months ago 1 Minute(s) to read